These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 27123743)

  • 1. Prospective clinical trial of hepatitis B vaccination in adults with and without type-2 diabetes mellitus.
    Van Der Meeren O; Peterson JT; Dionne M; Beasley R; Ebeling PR; Ferguson M; Nissen MD; Rheault P; Simpson RW; De Ridder M; Crasta PD; Miller JM; Trofa AF
    Hum Vaccin Immunother; 2016 Aug; 12(8):2197-2203. PubMed ID: 27123743
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and immunogenicity of a modified process hepatitis B vaccine in healthy adults ≥50 years.
    Gilbert CL; Klopfer SO; Martin JC; Schödel FP; Bhuyan PK
    Hum Vaccin; 2011 Dec; 7(12):1336-42. PubMed ID: 22185811
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunogenicity of a two-dose investigational hepatitis B vaccine, HBsAg-1018, using a toll-like receptor 9 agonist adjuvant compared with a licensed hepatitis B vaccine in adults.
    Jackson S; Lentino J; Kopp J; Murray L; Ellison W; Rhee M; Shockey G; Akella L; Erby K; Heyward WL; Janssen RS;
    Vaccine; 2018 Jan; 36(5):668-674. PubMed ID: 29289383
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of an age-response relationship to GSK's recombinant hepatitis B vaccine in healthy adults: An integrated analysis.
    Van Der Meeren O; Crasta P; Cheuvart B; De Ridder M
    Hum Vaccin Immunother; 2015; 11(7):1726-9. PubMed ID: 25996260
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunogenicity of HBV vaccine during stated shelf-life.
    Gloriani NG; Srinivasa K; Bock HL; Hoet B
    Southeast Asian J Trop Med Public Health; 2010 Jul; 41(4):876-82. PubMed ID: 21073062
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and immunogenicity of a recombinant hepatitis B vaccine manufactured by a modified process in renal pre-dialysis and dialysis patients.
    Gilbert CL; Stek JE; Villa G; Klopfer SO; Martin JC; Schödel FP; Bhuyan PK
    Vaccine; 2014 Nov; 32(48):6521-6. PubMed ID: 25252192
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunogenicity and safety of a 2-dose hepatitis B vaccine, HBsAg/CpG 1018, in persons with diabetes mellitus aged 60-70 years.
    Hyer RN; Janssen RS
    Vaccine; 2019 Sep; 37(39):5854-5861. PubMed ID: 31431412
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the effect of two different doses of recombinant hepatitis B vaccine on immunogenicity in healthy adults.
    Li J; Yao J; Shan H; Chen Y; Jiang ZG; Ren JJ; Xu KJ; Ruan B; Yang SG; Wang B; Xie TS; Li Q
    Hum Vaccin Immunother; 2015; 11(5):1108-13. PubMed ID: 25607773
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatitis B virus vaccination for older adults.
    Bennett RG; Powers DC; Remsburg RE; Scheve A; Clements ML
    J Am Geriatr Soc; 1996 Jun; 44(6):699-703. PubMed ID: 8642163
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and immunogenicity of co-administered quadrivalent human papillomavirus (HPV)-6/11/16/18 L1 virus-like particle (VLP) and hepatitis B (HBV) vaccines.
    Wheeler CM; Bautista OM; Tomassini JE; Nelson M; Sattler CA; Barr E;
    Vaccine; 2008 Jan; 26(5):686-96. PubMed ID: 18164106
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunogenicity and safety of a Haemophilus influenzae B (Hib)-hepatitis B vaccine with a modified process hepatitis B component administered with concomitant pneumococcal conjugate vaccine to infants.
    Lee AW; Vesikari T; Gilbert CL; Klopfer SO; Schödel FP; Bhuyan PK
    Vaccine; 2011 Oct; 29(45):7942-8. PubMed ID: 21875633
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunogenicity of a new, low-cost recombinant hepatitis B vaccine derived from Hansenula polymorpha in adults.
    Kulkarni PS; Raut SK; Patki PS; Phadke MA; Jadhav SS; Kapre SV; Dhorje SP; Godse SR
    Vaccine; 2006 Apr; 24(17):3457-60. PubMed ID: 16530299
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative study of the immunogenicity and safety of two doses of recombinant hepatitis B vaccine in healthy adolescents.
    Schiff GM; Sherwood JR; Zeldis JB; Krause DS
    J Adolesc Health; 1995 Jan; 16(1):12-7. PubMed ID: 7742331
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and immunogenicity of double-dose versus standard-dose hepatitis B revaccination in non-responding adults with HIV-1 (ANRS HB04 B-BOOST): a multicentre, open-label, randomised controlled trial.
    Rey D; Piroth L; Wendling MJ; Miailhes P; Michel ML; Dufour C; Haour G; Sogni P; Rohel A; Ajana F; Billaud E; Molina JM; Launay O; Carrat F;
    Lancet Infect Dis; 2015 Nov; 15(11):1283-91. PubMed ID: 26257021
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of two immunization schedules with recombinant hepatitis B vaccine and natural immunity acquired by hepatitis B infection in dialysis patients.
    el-Reshaid K; al-Mufti S; Johny KV; Sugathan TN
    Vaccine; 1994; 12(3):223-34. PubMed ID: 8165854
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of four recombinant hepatitis B vaccines applied on an accelerated schedule in healthy adults.
    Hernández-Bernal F; Aguilar-Betancourt A; Aljovin V; Arias G; Valenzuela C; de Alejo KP; Hernández K; Oquendo O; Figueredo N; Figueroa N; Musacchio A; Véliz G; García E; Mollineda AD; Juvier AI; Trujillo J; Delahanty A; Ortega D; Cinza Z; González VL
    Hum Vaccin; 2011 Oct; 7(10):1026-36. PubMed ID: 21941089
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenicity and reactogenicity of two recombinant hepatitis B vaccines in small infants: a randomized, double-blind comparative study.
    Sapru A; Kulkarni PS; Bhave S; Bavdekar A; Naik SS; Pandit AN
    J Trop Pediatr; 2007 Oct; 53(5):303-7. PubMed ID: 17478542
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunogenicity and Safety of a 3-Antigen Hepatitis B Vaccine vs a Single-Antigen Hepatitis B Vaccine: A Phase 3 Randomized Clinical Trial.
    Vesikari T; Finn A; van Damme P; Leroux-Roels I; Leroux-Roels G; Segall N; Toma A; Vallieres G; Aronson R; Reich D; Arora S; Ruane PJ; Cone CL; Manns M; Cosgrove C; Faust SN; Ramasamy MN; Machluf N; Spaans JN; Yassin-Rajkumar B; Anderson D; Popovic V; Diaz-Mitoma F;
    JAMA Netw Open; 2021 Oct; 4(10):e2128652. PubMed ID: 34636914
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunogenicity and safety of an investigational hepatitis B vaccine with a toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared with a licensed hepatitis B vaccine in patients with chronic kidney disease.
    Janssen RS; Mangoo-Karim R; Pergola PE; Girndt M; Namini H; Rahman S; Bennett SR; Heyward WL; Martin JT
    Vaccine; 2013 Nov; 31(46):5306-13. PubMed ID: 23727422
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of antigen dosage on the hepatitis B vaccine response in infants born to hepatitis B-uninfected and hepatitis B-infected mothers.
    Kang G; Ma F; Chen H; Yang Y; Guo S; Wang Z; Liang X; Li L; Cui F; Zhang L
    Vaccine; 2015 Aug; 33(33):4093-9. PubMed ID: 26144895
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.